Coronary heart disease prevention in type II primary hyperlipoproteinaemia'
The value of a dietary or drug-induced reduction in plasma cholesterol concentration as a preventive measure in coronary heart disease (CHD) has been debated for many years. The inconclusive results of early clinical trials emphasized the practical problems involved in the test of the hypothesis and the inescapability of rigorous attention to study design (Rinzler 1968 , Dayton et al. 1969 . Although diet is the preferred means of intervention, feasibility studies undertaken in the 1960s by the US National Heart Institute (later to become the National Heart, Lung and Blood Institute -NHLBI) demonstrated the impracticality of this approach in the general community (National Diet-Heart Study 1968, NHLBI Task Force on Arteriosclerosis 1971) and attention was focused on drug therapy as an alternative procedure.
A clinical trial of cholesterol-lowering drug therapy for prevention of CHD was planned as a major component of the Lipid Research Clinics programme of the NHLBI, along with population and clinical studies which were to prove of value in the trial design. The anion exchange resin cholestyramine was selected for this purpose, since 10 years of clinical experience had established its efficacy and safety in doses of 16 to 24 g/day (Bergen et al. 1959) , and an effective placebo was available. In order to provide a reasonable chance of demonstration of therapeutic effect on CHD incidence within 7 years, the trial was restricted to men aged 35-59 years with type II hyperlipoproteinaemia, defined from population data as a serum cholesterol concentration greater than 6.8 mmol/l (264 mg/dl) (Lipid Metabolism Branch of NHLBI 1980) . Half the participants received cholestyramine 24 g/day, while the remainder were given a placebo in a random, double-blind manner. The study ran between July 1973 and August 1983. Its findings and implications were presented to the Society's Forum on Lipids in Clinical Medicine on 26 June 1984 by Dr Robert Levy (New York) with commentary by Professor Michael Oliver (Edinburgh).
Few men with hypercholesterolaemia, and aware of their high risk of CHD, were expected to accept the 50% probability of prescription of no more than an inert substance for 7 years, especially among those already on a cholesterol-lowering diet. Thus, in an attempt to improve compliance 'Report of meeting of the Forum on Lipids in Clinical Medicine, 31 May 1984. Accepted 10 October 1984 and standardize diet, all men were prescribed a diet estimated to reduce plasma cholesterol by about 4%. A double-blind trial of cholestyramine in type II hyperlipoproteinaemia (Levy et al. 1973) had demonstrated an average 21 % reduction in plasma cholesterol at a dose of 16 g/day (less than used in the prevention trial). Assuming, therefore, 28% and 4% reductions in plasma cholesterol in treatment and control groups respectively, and an instantaneous effect of cholesterol reduction on CHD risk, then from the Framingham Study (Kannel et al. 1971 ) the respective 7-year incidence rates of non-fatal myocardial infarction and fatal CHD combined (the primary endpoint) were anticipated to be 39/1000 and 87/1000. Neither assumption was recognized as reasonable, however. Non-compliance would reduce the effectiveness of therapy, and the time for treatment to achieve maximum effect (F) would be years rather than days. These problems had been examined by the Biometrics Research Branch of the National Heart Institute, and tables (National Diet-Heart Study 1968 , Halperin et al. 1968 ) were available for allowance for F and non-compliance (assumed in the absence of data to be 3 years and 5% per year respectively). The adjusted incidence rate for the cholestyramine-plus-diet group was 56/1000, and the minimum sample required to provide a 90% chance of demonstration of statistical significance at P=0.01 was estimated to be 3550.
With this target in mind, recruitment commenced through physician and laboratory referral. After 9 months, however, only 74 (2%) participants had entered the trial. From then on recruitment was intensified, and the 12 Lipid Research Clinics sought alternative ways to identify candidates. Occupational groups, complete communities and blood banks were screened for eligible men. Advertisements were placed in the media. Mailing lists were employed, and recruitment resources were shared with other major studigs such as the Multiple Risk Factor Intervention Trial. In all, 436 679 age-eligible men responded to this drive, but it is impossible to define the baseline population from which these men were drawn. For example, 23 355 respondents were seen in response to a mailing campaign involving more than 650000 letters. Another 113000 men were obtained from 19 blood banks with an estimated turnover of more than 240000 per year. Community screening in Iowa achieved a 25% response yielding a further 12000 potential participants. i) 1985 The Royal Society of Medicine What is certain is that the eventual participants were atypical of the general community. About 57% were professionals, 95% were white, 92% were married and 88% were high school or college graduates.
Of the original 436 679 candidates, 18 013 had the requisite hypercholesterolaemia without hypertriglyceridaemia (i.e. triglyceride below 3.4 mmol/l or 300 mg/dl) and were without obvious serious illness. This subgroup qualified for a further 4 examinations at monthly intervals to ensure that their lipid status was persistent, not unduly sensitive to the dietary regimen (i.e. plasma low-density lipoprotein (LDL) cholesterol concentration remained above 4.5 mmol/l or 174 mg/dl on diet), and not secondary to other underlying disease such as diabetes mellitus. In addition, those with clinical CHD, hypertension, obesity, non-atherosclerotic heart disease, alcoholism or other evidence of serious ill health (according to strictly defined criteria) were unsuitable for entry. In the event, 59% were excluded on lipid criteria, 3% were rejected because of clinically apparent heart disease, 10% were unwilling to collaborate further, and 3810 (21%) met the criteria for entry. A further 4 were removed subsequently when type III hyperlipoproteinaemia became apparent.
To reduce the risk that men in the treatment and control groups might differ in distribution with respect to clinic of origin or other factors likely to be related to survival, participants were randomly assigned to one or other group by the random permuted block method within 96 strata. Essentially this meant that each of the 12 clinics had its own randomization schedule. This schedule contained six lists to which each recruit was referred on the basis of LDL cholesterol (above or below 5.56 mmol/l or 215 mg/dl), the ST segment response to graded exercise (positive or negative) and a critical value for a risk score given by a multiple logistic regression on age, diastolic blood pressure and smoking habit. The procedure was successful. For example, of 49 men in the upper stratum of all three CHD risk characteristics, 26 were in the treatment group and 23 in the placebo group. Mean baseline LDL and high-density lipoprotein (HDL) cholesterol concentrations in the treatment group were 5.65 and 1.14 mmol/l respectively, and in the control group 5.66 and 1.14 mmol/l respectively. Of 83 variables measured, only five showed a statistically significant difference between groups at P < 0.05. Four such differences can be expected to occur by chance alone at this level of probability. N6ne was of clinical importance, for example mean differences of 0.42 cm in height and 0.51 kg in weight.
There were 1906 men on cholestyramine and 1900 on placebo. Each was requested to attend their clinic at two-month intervals for the trial's duration. The 7-year incidence for the primary end-point was 81/1000 on treatment (45% higher than predicted) and 98/1000 on placebo (13% higher than predicted). The difference in incidence achieved statistical significance at P= 0.04. Instead of an expected reduction in incidence of 36% in the treatment group, the observed reduction after adjustment for follow-up time and stratification amounted to only about 19%. This figure is a best estimate. The weakness of the statistical end-point resulted in wide 90% confidence limits of 3% and 32%, which left considerable room for doubt as to the true strength of the effect of therapy on CHD prevention. However, the investigators noted consistent reductions in other cardiovascular events in men on cholestyramine, for example, a 20% decrease in incidence of angina and a 25% reduction in the development of a positive exercise ECG. This internal consistency provided a further clinical support for efficacy of treatment.
The main cause for the large discrepancy between predicted and observed results appeared to have been a failure to allow for partial compliance in the original calculation of trial size. In addition to the non-compliant men, some were unable to tolerate full dosage and were therefore given less than 24 g/day. Others simply neglected to adhere to the regimen. Thus the mean reduction in plasma cholesterol concentration in the cholestyramine group was only 18% in the first year, and decreased steadily thereafter to about 10% of baseline value in the seventh year. Many men returned unused packets of drug at clinic attendances. Statistical analysis was based on intention-to-treat', which meant that the outcome of each participant was taken into account irrespective of compliance during the trial. Had the organizers allowed for this effect and foreseen the true incidence rates, their estimate of men required would have been closer to 15000 than 3550 and the trial may well have been dismissed as impractical.
Questions were raised at the meeting about the use of a one-tailed test of statistical significance in the interpretation of results. In the cooperative clofibrate trial, for example, similar assumptions were made regarding untreated incidence rate, dropout rate and treatment effect, but a 1 % level of statistical significance was sought with a twosided test (Committee of Principal Investigators 1978). Partly for this reason the trial required about 5000 men in each group. Employment of a one-sided test in the Lipid Research Clinics trial implied that the investigators felt that sufficient was known about cholestyramine and about the characteristics of their placebo and test groups to be certain that any increase in CHD in the treatment group (no matter how large) could have occurred only by chance. As it happened, the reduction in incidence in men on cholestyramine was more than 18% in 7 clinics and between 5% and 15% in a further 4 clinics. In one clinic, incidence in the treatment group was 4% greater than in the controls, but this was the clinic with poorest compliance.
The reduction in CHD incidence in the treatment group applied to both non-fatal myocardial infarction and CHD death, although numbers were too few for the differences to achieve significance separately. Professor Oliver commented that ideally the two components of the primary endpoint should perhaps have been kept apart (even though coronary atherosclerosis was involved in both) because the underlying pathological processes are not identical. However, to do so would have meant either extension of the trial for several years or an increase in numbers of participants, neither of which was feasible.
There were 36 non-CHD deaths in the treatment group as compared with 27 in the controls (a 33% excess in those on cholestyramine). This result is of the same order as that reported for the clofibrate trial, in which the excess was due mainly to hepatobiliary and intestinal disease (Committee of Principal Investigators 1978). However, the excess in those on cholestyramine was due to 11 violent deaths (6 accidents, 4 suicides, I murder) as compared with 4 in the placebo group (2 accidents and 2 suicides). Post-mortem information available for 7 of the 8 accidents showed no evidence of recent myocardial infarction or coronary thrombosis. With regard to malignancy, the overall incidence was 30/1000 per 7 years in both groups. There were 15 oesophageal and gastrointestinal cancers in the treatment group as compared with 11 in the placebo group. Six in each group were colon cancers. On the basis of national statistics, about 17 oesophageal and gastrointestinal cancers would be expected in each group, but the relevance of national figures for groups so highly selected from the general population is open to debate. Professor Oliver expressed particular concern at the occurrence of 6 buccal cancers in the treatment group as compared with none in the placebo group (4 expected from national figures). Four of the men with this cancer were smokers, but this does not completely preclude a possible role for cholestyramine in this type of malignancy. There was general agreement about the need for careful follow up of all trial participants for perhaps another 5 years in order to monitor causes of death in both groups.
The wide range of reduction in total and LDL cholesterol concentration in the treatment group offered an opportunity to relate the response of plasma lipoproteins to CHD incidence. The 155 incidence cases in the cholestyramine group were grouped according to year of follow up in which the event occurred. Mean LDL cholesterol concentrations in each group were then compared with those for survivors who had not suffered a myocardial infarction. Apart from deaths during the first year and (inexplicably) in the sixth year, the CHD cases showed substantially smaller percentage reductions in LDL cholesterol than other men throughout surveillance. The percentage reduction in LDL cholesterol achieved appeared to be related to degree of compliance with therapy, from an average of 6.6% at 4 g/day or less, increasing steadily to 28.3% at 20 g/day or more. When both change in LDL cholesterol and mean daily packet count were used as explanatory variables of outcome in logistic regression, only the former term achieved statistical significance. Thus the change in LDL, rather than compliance per se, was the primary determinant of outcome. A small increase in HDL cholesterol on cholestyramine was incidentally found to be independently related to CHD incidence after allowance for LDL cholesterol concentration.
In summary, the trial provided good evidence to justify treatment to lower plasma cholesterol in middle-aged men with a concentration above the 95th percentile for the general community. The rule-of-thumb (suggested by epidemiological data in the early 1960s) was confirmed that a 1% reduction in plasma cholesterol concentration would reduce the incidence of CHD by about 2%. Inevitably, the relevance of this result for the remainder of the population will remain a subject for debate for it cannot be known for certain whether extrapolation of these findings to the general population is specious or not. However, as was pointed out at the meeting, there is nothing magical about the 95th percentile; what appears to matter is the absolute LDL cholesterol concentration and length of exposure. Individual risk of CHD declines with cholesterol concentration, but men with less unusual concentrations account for the bulk of CHD deaths. Clearly, with a disease which remains silent for so many years (in 33% of patients the only indication of its presence is sudden death) there remains a pressing need for better identification of those at risk. Until this is done, clinical trials of treatments designed to protect the majority of men from CHD will remain impractical. Food allergyfact or fancy?' A show of hands at the beginning of this debate of the Section of Clinical Immunology & Allergy indicated that the majority of those present supported the proposal of food allergy as fact. The proceedings were opened by Professor John Soothill (Hospital for Sick Children, London) who stated that to prove this case he needed to say very little. The original definition of allergy was of an altered state of reaction of the organism. This held for the many people who never sought medical attention but knew for themselves that certain foods produced urticaria. The first contact with any particular food produced allergens in the blood stream. Controlled experiments with encapsulated foodstuffs had shown the production of IgE antibody (May et al. 1980 ). However, the majority of food allergies were slow responses and therefore more difficult to demonstrate. Professor Soothill thought that the sceptics were largely searching for a single cause of a single disease, but most chronic diseases were multifactorial; food allergy contributed to many, although the mechanisms were as yet not established. A 'black box immunologist' was not only concerned with mechanisms but observed altered states of responsiveness of the whole organism following appropriate manipulations; such observations could be of great benefit to patients. Jenner certainly had no knowledge of immunological mechanisms but his original work led directly to the worldwide eradication of a major disease. The present data provided strong evidence that dietary treatment based on the allergy hypothesis was effective in many diseases and in untreated patients. The onus was now on those who questioned this. Professor Soothill's attitude was that current knowledge largely favoured food allergy as a fact which could be used to the benefit of a large number of patients.
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Professor Soothill felt that perhaps the debate should have been the other way round, with the proposer asserting that food allergy was fancy. He pointed out that much infantile colitis was almost certainly an allergy to cows' milk and occasionally to soya protein. He did not say that all infantile eczema was a food allergy, but in many infants and children the avoidance of certain foods, particularly milk and eggs, was beneficial, and this had been established by controlled trial (Atherton et al. 1978) . Studies had shown that breast-feeding reduced the prevalence of allergic disease, perhaps not only because of exclusion of allergens but because of the protective effect of immunological factors in the breast milk (Matthew et al. 1977) . The ability of sodium cromoglycate and oral beclomethasone to protect against infantile eczema was also a strong pointer towards food allergy as a cause, since both these drugs were only active within the gut. An important non-atopic condition related to food allergy was migraine; a doubleblind controlled trial based on the allergy hypothesis had shown that any food could provoke responses (Egger et al. 1983) . Although many nonspecific factors, including psychological ones, triggered migraine, such responsiveness was reduced by exclusion of the appropriate foods. The foods involved in many patients' illnesses supported the view that the response was allergic, not idiosyncratic, e.g. in some patients cows' cheese would cause migraine and sheeps' cheese would not.
The opposer, Professor Sam Shuster (Newcastle), was introduced as possessing qualities of immunological innocence and dermatological deviousness. He opened his address by pointing out that Professor Soothill epitomized the good scientist: one who was single-minded and with an ability to ignore fact. Professor Shuster concentrated his argument in the field of dermatology. There was no doubt that there were transmittable antibody responses in atopic eczema. However, most of these responses were urticarial and not eczematous and the key issue was whether the antibody response was necessarily harmful. There were many discrepancies in the field of eczema; it 'Report of meeting of the Section of Clinical Immunology & Allergy, 18 June 1984 . Accepted 8 November 1984 
